Peptides for MCAS and POTS: The Mast Cell and Autonomic Cluster

Officially, Mast Cell Activation Syndrome and Postural Orthostatic Tachycardia Syndrome are separate diagnoses. In practice, they show up in the same patients far more often than chance can explain. Published prevalence puts MCAS at lab criteria in up to 66% of POTS patients, and at activation-sign criteria in ~40%. Add hypermobile Ehlers-Danlos syndrome, which clusters with both, and you have the trifecta that fills dysautonomia clinic waiting rooms.

The overlap isn't coincidence. The biology connects through the autonomic-immune interface. Histamine stimulates vagal afferents and produces nausea and hypotension. Mast cell tryptase and chymase chew up neuropeptides that modulate sympathetic tone. Other mast cell mediators affect norepinephrine regulation. And the Theoharides group has shown that SARS-CoV-2 spike protein directly activates mast cells via ACE2 and TLR4, which is part of why Long COVID has exploded this population.

We're treating both conditions in one piece because the patient is the same patient. The wrinkle for peptide therapy: some peptides directly degranulate mast cells. The wrong choice can flare exactly what you're trying to treat.

The headline finding before any individual peptide: there are zero randomized controlled trials of any peptide in MCAS or POTS as a primary endpoint. The strongest human data anywhere in this space is a 47-patient retrospective case series of GLP-1 receptor agonists in MCAS, published in July 2025. Everything else is preclinical, anecdotal, or extrapolated from adjacent conditions like CIRS or IBD.

MCAS and POTS patients, often desperate after years of inadequate care, are routinely told peptides are a standard treatment. They aren't. The actual evidence ladder, strongest to weakest:

The GLP-1 finding is genuinely novel and deserves its own section.

The most important peptide development in MCAS in years isn't a new peptide. It's a repurposing of drugs millions of people already take.

Molderings, Afrin, and Dempsey published a case series of 47 MCAS patients on GLP-1 receptor agonists in the American Journal of the Medical Sciences in July 2025. Predominantly female (89%), mean age 39, mostly refractory to standard H1/H2 blockers and mast cell stabilizers. The findings:

• 89% clinical benefit rate
• Symptom improvement across inflammatory, neurologic, GI, and autonomic domains
• Benefit often within hours to days of the first dose
• Median weight loss 10.6% (max 36.9%); no patient became underweight

It was retrospective, not an RCT, and selection bias is substantial. But the size and speed of the effect — combined with two case reports of refractory chronic spontaneous urticaria resolving completely within 3 weeks of starting a GLP-1 (Dermatology and Therapy, 2025) — make this the strongest human signal in MCAS peptide therapy.

Mechanism is still being argued. The leading proposal is that GLP-1 receptors on mast cells receive a 'safety signal' that reduces degranulation. Rodent data supports this. Human mast-cell GLP-1R expression data is conflicting, so the effect could turn out to be indirect, working through inflammatory pathway modulation instead.

Clinically, Tania Dempsey and others have started using microdoses for immune modulation rather than weight-loss doses — tirzepatide 2 mg twice weekly, for example. Sub-therapeutic for obesity, but apparently active on mast cells. This is where the active clinical learning is happening, and it will likely be the dominant MCAS peptide conversation through 2026 and 2027.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone. Its mechanism in gut-related inflammation is genuinely clever: it's absorbed via the PepT1 di/tripeptide transporter, which is upregulated in inflamed intestinal epithelium. That means orally administered KPV preferentially accumulates in the tissue that needs it most — an elegant drug-delivery trick.

The landmark preclinical paper (Dalmasso et al., Gastroenterology 2008) demonstrated:

• Oral KPV reduced weight loss, colonic myeloperoxidase activity, and pro-inflammatory cytokine mRNA in DSS- and TNBS-colitis mice.
• Nanomolar concentrations were sufficient to inhibit NF-κB and MAPK activation and IL-8 secretion in intestinal epithelial and immune cell lines.
• Anti-inflammatory effects are not melanocortin-receptor mediated — the mechanism is post-entry NF-κB/MAPK inhibition, independent of MC1R/MC3R/MC4R/MC5R signaling.

The human evidence gap: There are no registered human trials of KPV in MCAS, IBD, or any GI inflammatory condition. Community protocols (Mind Body Neurology, Marty Ross MD, functional medicine clinics) use oral KPV at 250–500 mcg 1–2x/day, intranasal sprays at ~250 mcg/spray, and sublingual formulations. None of these doses have been tested in a dose-finding study.

KPV is popular in MCAS circles specifically because it targets gut inflammation — and gut-derived immune activation is one of the proposed drivers of systemic MCAS flares. First-person recovery narratives (Diary of Recovery 2024) describe resolution of "4 AM histamine dumps," elimination of famotidine, and food reintroduction after several months of consistent KPV use. These are anecdotes, not trial data, but the pattern is consistent enough across reports to warrant serious clinical attention.

Vasoactive intestinal peptide sits in an awkward spot in MCAS/POTS care. The Shoemaker CIRS protocol use suggests real therapeutic value for the autoimmune/autonomic cluster. It is also a well-documented direct human skin mast cell secretagogue.

On the Shoemaker side: intranasal compounded VIP (50 mcg/spray, 4–8x/day) is the final step of the 12-step CIRS protocol. The 2013 paper documented that VIP lowers TGF-β1, MMP-9, C4a, and VEGF; improves pulmonary artery pressure on exercise; and corrects ADH/osmolality. The last point matters directly for POTS orthostatic intolerance. The data covers thousands of patients in a single practice; no RCT has been done.

On the degranulation side: Church et al. (Immunology 1989) characterized direct histamine release from human skin mast cells in response to substance P, VIP, somatostatin, neurotensin, and compound 48/80. The mechanism is G-protein-coupled, pertussis-toxin-sensitive, PKC-dependent, largely calcium-independent, and completes in 10–20 seconds. Distinct from IgE-mediated degranulation.

For the MCAS-POTS overlap patient that creates a real tension: VIP may stabilize the autonomic system while provoking a mast cell flare. Clinicians who see this cluster regularly typically pre-medicate with H1/H2 blockers and cromolyn for 1–2 weeks before introducing VIP, then start at sub-standard doses. Even with that protocol, a minority of patients can't tolerate VIP and have to discontinue.

Aviptadil — the IV/inhaled synthetic VIP from NRx/Relief Therapeutics — failed in NIH ACTIV-3b for critical COVID. No aviptadil trials are active in MCAS or POTS.

BPC-157 is ubiquitous in MCAS/POTS protocols — typically stacked with KPV as a foundational anti-inflammatory pair. The preclinical rationale is real:

• Sikiric group's work on the brain-gut axis demonstrates vagal and dopaminergic normalization in rodent models (PMC10224484).
• Angiogenesis, barrier repair, and cytokine modulation are well-documented in animal studies.
• Some preclinical mast-cell-stabilizing claims exist, though these have not been well-replicated in high-quality models.

The human evidence gap is severe. No MCAS trial exists. No POTS trial exists. The single human IBD Phase 2 study from Pliva/Croatia was completed but never published in a peer-reviewed journal — a significant red flag for an active therapeutic claim. Development stalled after Pliva's acquisition by Barr/Teva.

Regulatory status: BPC-157 was removed from FDA Category 2 on April 22, 2026 after nominators withdrew their submissions. This is not an approval for 503A compounding. The Pharmacy Compounding Advisory Committee will review BPC-157 on July 23, 2026 to decide whether to add it to the 503A bulks list. Until then, legal compounding access remains ambiguous — clinics marketing BPC-157 as "now legal" are overstating the status.

Community signal in MCAS/POTS populations: Unlike the ME/CFS population (where Phoenix Rising documents serious crash reports from BPC-157), MCAS/POTS community feedback is more mixed. The Mind Body Neurology clinic protocol — BPC-157 + KPV started sequentially — is widely cited. But within MCAS, any injectable peptide carries degranulation risk from both the peptide itself and the formulation excipients (see next section).

This is the part of the conversation that gets skipped most often, and it matters most. Some peptides are direct mast cell secretagogues and reliably trigger flares in MCAS patients. Church et al. (1989) characterized the mechanism: pertussis-toxin-sensitive, G-protein-coupled, calcium-independent histamine release, completing in 10–20 seconds.

The known direct activators include substance P (the archetypal neuropeptide trigger), VIP (despite its therapeutic use in CIRS), somatostatin and its analogs (octreotide, lanreotide), neurotensin, compound 48/80 (a research compound), poly-L-lysine and other cationic peptides, MCD peptide from bee venom, and morphine (not a peptide but the same pathway).

The shorter list — peptides with documented post-injection histamine flush — is more clinically relevant. CJC-1295 + Ipamorelin sits at the top. The growth-hormone-secretagogue combo produces facial and upper-chest flush in a substantial minority of users, attributed to direct mast cell degranulation. Ipamorelin was specifically designed to be 'selective' (less prolactin/cortisol release than GHRP-6), but selective doesn't mean histamine-sparing. In MCAS patients this is a predictable trigger. Anecdotal reports of severe flush and flare on CJC/Ipamorelin in MCAS populations are widespread.

The rule of thumb: any cationic or amphipathic peptide is a theoretical mast cell risk in MCAS. Before starting a new peptide, challenge with a microdose (10% of standard) and pre-medicate with H1/H2 blockers.

A peptide that doesn't directly release histamine can still trigger an MCAS flare through its formulation. Three excipients show up across compounding pharmacies as common culprits.

Mannitol is a common lyophilization bulking agent, and it's hyperosmolar — which drives nonspecific mast cell and basophil degranulation. Same mechanism the Aridol bronchoprovocation test exploits to diagnose asthma. Mannitol can also trigger true IgE-mediated anaphylaxis in sensitized individuals (Calogiuri 2005, Hegde 2007).

Metacresol is the preservative in multidose insulin and some compounded peptide vials. It causes both Type I (immediate) and Type IV (delayed) hypersensitivity. Documented reactions include skin reactions, headache, nausea, diarrhea, and exfoliative dermatitis.

Polyethylene glycol shows up in PEGylated peptides and as an excipient. Anti-PEG IgE and IgG antibodies drive mast cell and basophil activation. Hypersensitivity rate for PEG-liposomal doxorubicin is 5–10%. Anti-PEG antibody prevalence has been climbing post-COVID-vaccine, which makes this a more common issue than it used to be. MCAS patients should specifically ask whether any peptide formulation contains PEG.

Practically, single-dose vials without preservatives are preferable to multidose metacresol-preserved ones. Compounded formulations with sterile water and minimal excipients are usually safer than commercial preparations optimized for shelf-life. If you react to one peptide and not another with the same active compound, the excipient is often the explanation.

POTS has even less peptide-specific research than MCAS. The clinical picture is dominated by non-peptide interventions: volume expansion (salt, fluids, midodrine), beta-blockers, ivabradine, and increasingly low-dose naltrexone. Peptide use is almost entirely extrapolation.

Active peptide-pathway POTS trial: REGN7544 (anti-NPR1 monoclonal antibody from Regeneron, NCT06593600) is the only registered trial specifically targeting a peptide system in POTS. It's in Phase II, recruiting since late 2024. Natriuretic peptide antagonism targets the atrial natriuretic peptide / B-type natriuretic peptide system, which modulates fluid balance and sympathetic tone. Results pending.

Community-used peptides for POTS:

• BPC-157 — for vagal modulation and gut-brain axis. BioReset Medical and similar clinics use 500–1000 mcg ranges. No trial data.
• CJC-1295 / Ipamorelin for sleep — but with the MCAS histamine caveat. Many POTS patients have sleep disturbance, and GH secretagogues improve sleep architecture in general populations. In POTS patients, the autonomic effects (mild tachycardia, cortisol shifts) may offset sleep benefits.
• Oxytocin — intranasal oxytocin increased HRV in men at clinical high risk for psychosis (Translational Psychiatry 2020). Mixed results in other populations. Some POTS clinicians prescribe compounded intranasal oxytocin; data is thin.
• Selank — Russian anxiolytic with enkephalinase-inhibition mechanism. One GAD/neurasthenia study (Zozulia 2008) noted autonomic symptom improvement. No POTS trial.
• DSIP — blood pressure and HPA modulation claims at Wikipedia-level evidence. No POTS data.

The honest POTS peptide conclusion: There is no peptide with demonstrated POTS efficacy. REGN7544 may change that, but it's a monoclonal antibody against a peptide receptor, not a peptide therapeutic itself. Community protocols targeting POTS with BPC-157 and oxytocin sit at the speculative end of the evidence spectrum.

For patients navigating MCAS and POTS with peptide interest, a few clinicians are the most-cited experts:

• Lawrence Afrin, MD — co-author on the 2025 GLP-1 MCAS case series and longstanding MCAS specialist. His 2017 MCAS classification paper remains foundational. Currently at AIM Center for Personalized Medicine.
• Tania Dempsey, MD — AIM Center (same practice as Afrin). The most vocal clinician champion of GLP-1 receptor agonists for MCAS. Maintains a peptide therapy page on her practice site.
• Anne Maitland, MD, PhD — Mt. Sinai / Comprehensive Allergy and Asthma Care (Tarrytown, NY). Particular focus on MCAS + hEDS/HSD intersection. Published on neuropsychiatric manifestations of MCAS.
• Ritchie Shoemaker, MD — CIRS protocol originator, including intranasal VIP. Retired from clinical practice but his protocol is widely adopted.

Standard-of-care stack (for context, none of these are peptides):

1. H1 and H2 antihistamines (cetirizine/loratadine + famotidine)
2. Cromolyn sodium and/or ketotifen 1 mg qhs titrated to 1 mg bid
3. Low-dose naltrexone 2 mg → 4.5 mg qhs titration
4. Consider low-dose aripiprazole (LDA), quercetin, luteolin

Peptide therapy is most defensible as an adjunct to this standard stack, not a replacement. Patients who have not trialed the standard antihistamine and mast cell stabilizer protocol shouldn't be starting with peptides — the evidence base for the standard of care is substantially stronger.

MCAS and POTS sit in an unusually difficult spot in peptide medicine. The patient population is large and underserved. The clinical need is real. And the rigorous evidence for peptide therapy is almost nonexistent.

GLP-1 receptor agonists are the strongest emerging signal in MCAS. The Molderings/Afrin/Dempsey case series deserves attention — 89% benefit in a 47-patient refractory cohort isn't nothing, and the speed of response (hours to days) is unusual. Microdose protocols are where the active learning is happening.

KPV has genuine mechanistic elegance through PepT1 transporter targeting of inflamed gut, and community use is consistent across reports. Zero human trials in MCAS or any inflammatory condition.

VIP in the Shoemaker CIRS framework has two decades of observational support and also directly releases histamine. It needs pre-medication and microdosing to be usable.

BPC-157 has strong preclinical data and mixed MCAS community feedback. The April 2026 FDA Category 2 removal isn't compounding approval — clinics presenting it as such are wrong.

CJC-1295 / Ipamorelin should be approached carefully or avoided in MCAS. The histamine flush is well-documented.

Formulation excipients matter. Mannitol, metacresol, and PEG can drive flares independent of the active peptide.

POTS has no peptide with demonstrated efficacy. REGN7544 may be the first.

The honest framing for patients: peptides are an experimental adjunct to standard MCAS/POTS care, not a replacement. The research hasn't caught up to community enthusiasm, and in a population this reaction-prone, that gap matters more than in most peptide therapeutics.